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Fulminant meningococcal sepsis has been termed the prototypical lipopolysaccharide (LPS)-mediated gram-
negative septic shock. Systemic inflammation by activated complement and cytokines is important in the
pathogenesis of this disease. We investigated the involvement of meningococcal LPS in complement activation,
complement-dependent inflammatory effects, and cytokine or chemokine production. Whole blood anticoagu-
lated with lepirudin was stimulated with wild-type Neisseria meningitidis H44/76 (LPS), LPS-deficient N.
meningitidis H44/76lpxA (LPS), or purified meningococcal LPS (NmLPS) at concentrations that were relevant
to meningococcal sepsis. Complement activation products, chemokines, and cytokines were measured by
enzyme-linked immunosorbent assays, and granulocyte CR3 (CD11b/CD18) upregulation and oxidative burst
were measured by flow cytometry. The LPS and LPS N. meningitidis strains both activated complement
effectively and to comparable extents. Purified NmLPS, used at a concentration matched to the amount present
in whole bacteria, did not induce any complement activation. Both CR3 upregulation and oxidative burst were
also induced, independent of LPS. Interleukin-1 (IL-1), tumor necrosis factor alpha, and macrophage
inflammatory protein 1 production was predominantly dependent on LPS, in contrast to IL-8 production,
which was also markedly induced by the LPS meningococci. In this whole blood model of meningococcal
sepsis, complement activation and the immediate complement-dependent inflammatory effects of CR3 upregu-
lation and oxidative burst occurred independent of LPS.
Invasive disease caused by the gram-negative bacterium
Neisseria meningitidis is a life-threatening infection in children
and young adults. Meningococcal septic shock (or fulminant
meningococcal sepsis [FMS]), the prototype of overwhelming
gram-negative sepsis, is feared especially because it is able to
cause devastating disease with a high case fatality rate. The
pathogenic mechanisms leading to FMS are thought to be the
uncontrolled growth of meningococci in the circulation, result-
ing in a massive activation of diverse inflammatory systems,
such as the complement system, the cytokine network, and the
coagulation cascade (6, 35).
In FMS, high lipopolysaccharide (LPS) levels are correlated
with an increased bacterial load, high levels of pro- and anti-
inflammatory cytokines, increased complement activation, the
induction of intravascular coagulation, and a poor outcome.
Therefore, meningococcal LPS is regarded as the principal
bacterial pathogenic element during FMS (3).
The complement cascade plays a dual role in the pathogen-
esis of meningococcal infections. A complement deficiency
predisposes some individuals to meningococcal infection (10,
17, 28), but on the other hand, with FMS, extensive comple-
ment activation is correlated with severe disease and a poor
outcome (4, 16). Thus, the complement system plays an im-
portant role in the first line of defense against meningococcal
infection, whereas massive activation of the complement sys-
tem contributes to the development of shock.
Complement is activated on the meningococcal surface by
one or more of the three initial complement-activating path-
ways, i.e., the classical, the lectin, and the alternative pathways
(Fig. 1). After the activation of complement factor 3 (C3) by
any of these pathways, a C5 convertase is formed, which
cleaves the pivotal C5 molecule into C5a and C5b. C5b is the
initial molecule in the formation of the terminal C5b-9 com-
plement complex (TCC). Membrane-associated TCC, also des-
ignated the C5b-9 membrane attack complex, leads to lysis of
the bacterium, whereas C5a is a potent anaphylatoxin (24).
Experimentally, the role of the complement system in inflam-
mation by N. meningitidis and Escherichia coli was recently
given more emphasis by our observation that granulocyte CR3
(CD11b/CD18) upregulation and the formation of reactive
oxygen species in human whole blood, key elements in the
induction of vascular damage during sepsis, are highly depen-
dent on C5a (22, 29).
Recent in vitro studies suggested that components of N.
meningitidis other than LPS may also contribute to the inflam-
matory response of the host. Using a meningococcal mutant
that was deficient for LPS in the outer membrane, we and
others have shown that proinflammatory cytokines can be in-
duced independent of LPS in cultured human cells (27, 30, 34).
In addition, we showed that purified meningococcal LPS
(NmLPS) is a poor activator of complement, whereas experi-
ments with outer membrane vesicles that were depleted of or
completely lacking LPS suggested that non-LPS components in
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the bacterial outer membrane are the principal complement
activators in a whole blood model (1).
For the present study, LPS-containing N. meningitidis, LPS-
deficient N. meningitidis, and purified meningococcal LPS were
used in a human whole blood model of meningococcal sepsis to
determine the role of LPS in complement activation, the com-
plement-dependent inflammatory processes of CR3 upregula-
tion and oxidative burst, and cytokine production.
(Part of this study was presented at the Joint Meeting of the
Belgian and Dutch Societies for Immunology, Veldhoven, The
Netherlands, 18 to 20 December 2002.)
MATERIALS AND METHODS
Equipment and reagents. All materials used in the stimulation experiments
were endotoxin-free. The polypropylene tubes used were either Nunc cryotubes
(Nalgene Nunc, Roskilde, Denmark) or Falcon tubes (Becton Dickinson, Frank-
lin Lanes, N.Y.). Phosphate-buffered saline (PBS) was produced in the labora-
tory, Dulbecco’s medium was obtained from Invitrogen Corporation (Paisley,
Scotland), and lepirudin (Refludan) was purchased from Hoechst (Frankfurt am
Main, Germany). Flow cytometry was performed with a FACScalibur instrument
(Becton Dickinson San Jose, Calif.), and optical densities were determined with
an MRX microplate reader (Dynex Technologies, Denkendorf, Germany).
Bacterial strains. N. meningitidis H44/76 (LPS) is an isolate from a patient
with invasive meningococcal disease (18). This strain is the production strain for
the Norwegian group B OMV vaccine and is an international reference strain
(11), serologically classified as B:15:P1.7,16, immunotype L3,7,9, as determined
by the use of anti-LPS monoclonal antibodies (MAbs) in a dot blotting assay for
immunotyping (40). The LPS-deficient strain N. meningitidis H44/76lpxA (LPS)
is a viable isogenic mutant of strain H44/76 that lacks LPS in the outer membrane
and was a kind gift from Peter van der Ley and Liana Steeghs (Dutch Vaccine
Institute, Bilthoven, The Netherlands). It was constructed by insertional inacti-
vation of the lpxA gene, which is essential for the first committed step of bio-
synthesis of LPS, as described by Steeghs et al. (32). For the present study, batch
suspensions of H44/76lpxA were tested and showed no reactivity in a Limulus
amebocyte lysate (LAL) assay, a highly specific and sensitive test for LPS. As
shown by Steeghs et al., the expression level of the integral outer membrane
proteins by the LPS-deficient mutant is similar to that of the wild-type strain;
however, the outer membrane phospholipid composition is altered, with a switch
to mostly short-chain, saturated fatty acids (31). LPS-deficient mutant meningo-
cocci were grown overnight on Kellog’s medium and resuspended in Hanks’
balanced salts solution (Invitrogen). Bacteria were heat inactivated at 60°C for 40
min. The concentration of the bacteria was determined by measuring the optical
density at 630 nm. NmLPS was isolated from strain H44/76 by phenol-water
extraction (41) followed by DNase, RNase, and proteinase K treatment. The
batch of LPS used for this study was previously shown to be highly reactive in the
LAL assay and a potent inducer of cytokine production (2). Quantification of the
amount of LPS in LPS N. meningitidis H44/76 bacteria was performed by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) fol-
lowed by silver staining of LPS. The LPS level was determined by digital scan-
ning, with purified H44/76 LPS used as the standard (30, 33).
Whole blood model. A recently developed whole blood model for the study of
N. meningitidis-induced inflammation was used (29). The model is based on
anticoagulation with lepirudin, a recombinant hirudin which is a highly specific
thrombin inhibitor that minimally influences complement activation or cytokine
production. Whole blood from healthy, adult volunteers was collected in
polypropylene tubes containing lepirudin (50-g/ml final concentration). In-
formed consent was obtained from all donors prior to the experiments, and the
human experimentation guidelines of the local ethics committee were followed in
conducting the research. Immediately after being drawn, the whole blood (1 ml)
was incubated with the stimulants (0.1 ml).
For the determination of granulocyte CR3 (CD11b/CD18) expression and
oxidative burst, samples were incubated for 10 min at 37°C in a water bath,
followed by immediate processing for flow cytometry.
For the detection of complement activation, samples were incubated for 1 h at
37°C in a Coulter mixer (Coulter, Luton, England). Complement activation was
stopped by the addition of EDTA to a final concentration of 20 mM, after which
samples were centrifuged at 1,400  g for 10 min. The plasma was collected and
stored at 70°C until samples were assayed in one batch.
Samples for the measurement of tumor necrosis factor alpha (TNF-), inter-
leukin-1 (IL-1), IL-8, and macrophage inflammatory protein 1 (MIP-1)
were processed as described for complement activation, but the incubation time
was increased to 2 h.
Oxidative burst. Oxidative burst was measured by using a commercially avail-
able Burst-test kit (Orpegen Pharma, Heidelberg, Germany). After incubation as
described above, samples were treated according to the manufacturer’s instruc-
tions and assayed by flow cytometry. Granulocytes were identified in a forward
scatter-side scatter plot by their typical patterns.
CR3 (CD11b/CD18) expression. After being incubated as described above,
cells were washed once in sterile PBS and fixed with 0.5% (vol/vol) paraformal-
dehyde in an equal volume of PBS for 4 min at 37°C. Cells were stained with an
anti-CD11b-PE or isotype control (2a) (Becton Dickinson) antibody for 15 min
at room temperature. An anti-CD14-FITC (Becton Dickinson) antibody and the
nuclear dye LDS-751 (Molecular Probes Inc., Eugene, Oreg.) were used to
discriminate granulocytes in washed whole blood.
Enzyme immunoassays. Complement activation was measured in plasma by
enzyme immunoassays based on MAbs that were highly specific for the activation
products; the native, nonactivated components did not interfere in the assays.
Activation of the three initial pathways was selectively detected.
(i) C1rs-C1inh complexes. Activation of the classical complement pathway was
determined as described previously (12). C1rs-C1 inhibitor (C1rs-C1inh) com-
plexes were measured by using MAb Kok-12, specific for a neoepitope exposed
only when C1inh is in complex with its substrates. In brief, microtiter plates were
coated with the Kok-12 antibody, the antibody was reacted with plasma or
controls, and the complex was detected with a cocktail of anti-C1r and anti-C1s
antibodies. Human serum activated with heat-aggregated immunoglobulin G was
used as a standard and was defined to contain 1,000 arbitrary units (AU)/ml.
(ii) C4bc. Activation of the classical and lectin pathways was determined by an
assay using a MAb specific for a neoepitope that is exposed in activated C4 (42).
The C4bc assay detects the sum of the activation products C4b, iC4b, and C4c.
The same standard was used as for the C1rs-C1inh assay, defined to contain 1,000
AU/ml. Both the MAb for this assay and Kok-12 were a kind gift from C. E.
Hack, Department of Immunopathology, Sanquin Research, Amsterdam, The
Netherlands.
(iii) C3bBbP complexes. Activation of the alternative pathway was detected by
measuring the alternative convertase C3b-Bb-properdin (C3bBbP), as recently
described (22). The capture antibody used was an antiproperdin antibody, and
the detection antibody was a polyclonal anti-C3 antibody. The standard was
normal human serum activated with zymosan and defined to contain 1,000
AU/ml.
(iv) TCC. Activation of the terminal pathway was quantified by using MAb
aE11, specific for C9 incorporated in the fluid-phase SC5b-9 complex, as de-
scribed previously (23). The assay was modified, with a biotinylated anti-C6
antibody used as the detection antibody. Human serum activated with zymosan
was used as the standard.
FIG. 1. Schematic overview of the complement system. Boxes in-
dicate specific complement activation products measured in the
present study and their relation to specific complement activation
pathways. C1rs-C1inh complexes reflect classical pathway activation,
C4bc reflects both classical and lectin pathway activation, and C3bBbP
reflects alternative pathway activation. TCC is an activation product of
the final common and terminal pathways.
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An overview of the complement activation markers measured is illustrated in
Fig. 1.
Cytokines and chemokines. Commercially available enzyme-linked immu-
nosorbent assay (ELISA) kits were used according to the manufacturers’ instruc-
tions to quantify TNF-, IL-1, IL-8 (Duo Set ELISA development system
[R&D Systems, Minneapolis, Minn.] for all three), and MIP-1 (MIP-1 Cyto-
screen [Biosource International, Cammarillo, Calif.]). The lower limits of detec-
tion were 8 pg/ml for TNF-, IL-1, and IL-8 and 2 pg/ml for MIP-1.
LAL assay. Quantification of the biological activity of LPS in the bacterial
strains was performed as described previously (5). E. coli O55:B5 LPS was used
as a reference. The lower limit of detection was 0.25 endotoxin units/ml.
Statistics. A two-way analysis of variance (ANOVA) for repeated measures
was used to test the data for statistically significant differences. P values of 0.05
were considered statistically significant.
RESULTS
Complement activation by LPS and LPS N. meningitidis
or purified NmLPS. Assays for C1rs-C1inh (classical pathway),
C4bc (classical and lectin pathways) and C3bBbP (alternative
pathway) complexes were used to determine the initial com-
plement activation pathways, whereas soluble TCC, the final
product of the terminal pathway, was used as an indicator of
total complement activation (Fig. 1).
The amount of LPS per 106 N. meningitidis cells was esti-
mated by SDS-PAGE analysis; this showed that 106 bacteria
contained approximately 5 ng of LPS. In Fig. 2 and 3, the x axes
are calibrated for the numbers of LPS N. meningitidis cells as
well as the amounts of LPS that are present in the bacteria. In
this way, the activities of the bacteria and purified LPS can be
compared quantitatively.
The levels of the markers of initial pathway activation, C1rs-
C1inh, C4bc, and C3bBbP, as well as that of TCC from the
terminal pathway, were all increased from the baseline after
stimulation with LPS or LPS N. meningitidis (Fig. 2). The
activation of initial complement activation products was seen
at concentrations of 106 meningococci/ml or higher, which
correspond to approximately 5 ng of NmLPS or more/ml. In
contrast, purified NmLPS did not induce complement activa-
tion at concentrations up to 1,000 ng/ml. The combination of
purified NmLPS and LPS N. meningitidis induced comple-
ment activation to a similar extent as LPS or LPS N. men-
ingitidis (not shown). These data indicate that complement
activation by N. meningitidis in human whole blood occurs
independently of the LPS outer membrane component.
Granulocyte CR3 upregulation and oxidative burst by LPS
and LPS N. meningitidis or purified NmLPS. Recently, the
CR3 upregulation and oxidative burst induced by N. meningi-
tidis in granulocytes were shown to be complement dependent
(29). Therefore, we investigated the role of LPS in these pro-
cesses.
Both LPS and LPS N. meningitidis at concentrations of
106/ml induced marked granulocyte CR3 upregulation and ox-
idative burst. The addition of purified NmLPS to LPS-deficient
N. meningitidis did not influence the CR3 upregulation or
oxidative burst (not shown). Notably, purified NmLPS did not
induce significant CR3 upregulation or oxidative burst at con-
centrations up to 1,000 ng/ml (Fig. 3). These results indicate
that the upregulation of CR3 expression and the oxidative
burst in whole blood granulocytes after stimulation with N.
meningitidis are not dependent on NmLPS.
Cytokine and chemokine induction by LPS and LPS N.
meningitidis. Cytokine and chemokine induction in a human
whole blood model of meningococcal sepsis was assessed after
FIG. 2. Complement activation by LPS and LPS N. meningitidis
and by purified NmLPS. The results are for the formation of C1rs-
C1inh (classical pathway), C4bc (classical and lectin pathways),
C3bBbP (alternative pathway), and TCC (final common pathway) after
the stimulation of lepirudin-treated human whole blood for 1 h with
LPS (diamonds) or LPS (squares) N. meningitidis or purified
NmLPS (circles). The x axes are calibrated for the numbers of LPS N.
meningitidis cells as well as the amounts of NmLPS that are present in
the LPS bacteria, according to SDS-PAGE analysis. Medians and
upper quartiles are presented from four separate experiments. *, P 
0.05; **, P 0.01, by two-way ANOVA. Dashed lines indicate baseline
complement activation.
FIG. 3. Granulocyte CR3 upregulation and oxidative burst by
LPS and LPS N. meningitidis and by purified NmLPS. The results
are for CR3 (CD11b/CD18) upregulation and oxidative burst in hu-
man granulocytes after the stimulation of lepirudin-treated human
whole blood for 10 min with LPS (diamonds) or LPS (squares) N.
meningitidis or purified NmLPS (circles). The x axes are calibrated for
the numbers of LPS N. meningitidis cells as well as the amounts of
NmLPS that are present in the bacteria, according to SDS-PAGE
analysis. One representative of three separately performed experi-
ments is shown. Dashed lines indicate baseline CR3 expression or
oxidative burst.
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2 h of incubation with LPS or LPS N. meningitidis (Fig. 4).
No cytokine or chemokine production was seen in this whole
blood model in the absence of a stimulus. LPS N. meningitidis
was a potent inducer of IL-1, TNF-, IL-8, and MIP-1
production, as it was able to induce cytokine and chemokine
production at concentrations higher than 104 meningococci/ml.
IL-1, TNF-, IL-8, and MIP-1 production by LPS menin-
gococci was significantly reduced compared to that by LPS N.
meningitidis (P  0.05 for all cytokines and chemokines mea-
sured). However, marked IL-8, and to a lesser extent, TNF-
and MIP-1 production was also induced by LPS N. menin-
gitidis, suggesting that these mediators can also be induced in
the absence of LPS (Fig. 4).
DISCUSSION
The principal finding of the present study was that comple-
ment activation and the complement-dependent inflammatory
events of CR3 upregulation and oxidative burst are indepen-
dent of LPS in a whole blood model of meningococcal sepsis.
The construction of the LPS-deficient meningococcal mu-
tant H44/76lpxA has made it possible to study the relative
importance of the LPS moiety of a gram-negative bacterium in
diverse inflammatory processes (32). We used LPS-deficient N.
meningitidis to assess the involvement of meningococcal LPS in
complement activation, complement-dependent inflammatory
effects, and cytokine or chemokine production in a human
whole blood model of meningococcal sepsis. The lack of reac-
tivity of the LPS strain in a LAL assay confirmed the absence
of LPS in the batch used for the experiments. The estimate that
106 LPS meningococci contained approximately 5 ng of me-
ningococcal LPS was in line with previous estimations (2, 30).
N. meningitidis is exclusively a human commensal or patho-
gen, and none of the animal models available accurately sim-
ulate FMS. Therefore, we used an in vitro experimental system
approaching, as closely as possible, the human in vivo situation
(22, 29). The principle of this model is to keep all ambient
inflammatory systems intact so that they can be activated and
mutually interact but still to avoid coagulation. Because most
anticoagulants, such as EDTA, citrate, and heparin, interact
with critical steps in the inflammatory network, this model uses
the highly specific thrombin inhibitor lepirudin, a recombinant
hirudin analogue, as an anticoagulant. CR3 upregulation and
oxidative burst were found to be induced to a similar extent by
live or heat-inactivated bacteria in this model. Since these
processes are highly complement dependent, this indicates that
complement activation is also not affected by inactivation of
the bacteria. Therefore, heat-inactivated bacteria were used
because of practical considerations, as live meningococci con-
stitute a significant health hazard (29).
LPS is present in solution in the form of micellar structures,
which is quite distinct from its organization when it is present
in the outer membrane. Hypothetically, the physicochemical
presentation of LPS could affect the complement-activating
ability, favoring membrane-bound LPS as the stronger com-
plement activator. However, the observation that LPS-contain-
ing meningococci activate complement to a similar extent as
LPS-deficient meningococci suggested that this is not the case,
as did the absence of an increase in the complement-activating
ability when isolated LPS was added back to the LPS-deficient
strain. This is supported by a previous study in which neisserial
outer membrane vesicles (OMVs) containing LPS were equi-
potent to OMVs deficient for LPS (1).
Complement activation by LPS or LPS N. meningitidis
was seen at concentrations of 106/ml or higher. This is a con-
centration of meningococci that is frequently found during
FMS (3, 13); 106 LPS N. meningitidis cells contain approxi-
mately 5 ng of LPS. In contrast, complement was not activated
by purified LPS at concentrations up to 1,000 ng/ml. This
suggests that during meningococcal sepsis, complement acti-
vation is not induced by LPS, but by other constituents of N.
meningitidis.
Members of our laboratory previously reported that the up-
regulation of CR3 and the induction of oxidative burst in
granulocytes in this whole blood model are dependent on com-
plement activation (22, 29). When complement is activated,
C5a is formed, and this anaphylatoxin reacts with the C5a
receptor on granulocytes and monocytes to induce the upregu-
lation of CR3. CR3 is the principal receptor involved in the
phagocytosis of C3b-coated bacteria, and when upregulated, it
will enhance phagocytosis of the bacteria and in this way stim-
ulate the oxidative burst process. Our results indicate that CR3
expression and oxidative burst are mediated by non-LPS com-
ponents of N. meningitidis.
It is commonly accepted that LPS extracted from diverse
gram-negative bacteria activates complement readily via clas-
sical and alternative pathway-dependent mechanisms (25, 38).
In addition, LPS has been shown to be able to upregulate CR3
expression and to prime neutrophils for oxidative burst (8, 9,
19, 21). However, for the experiments presented in these stud-
FIG. 4. Cytokines and chemokines induced by LPS and LPS N.
meningitidis. The results are for the production of IL-1, TNF-, IL-8,
and MIP-1 after the stimulation of lepirudin-treated human whole
blood for 2 h with LPS (diamonds) or LPS (squares) N. meningitidis.
Mean cytokine or chemokine production levels from three separate
experiments are presented. *, P  0.05, by two-way ANOVA.
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ies, very high concentrations of LPS were applied (	5 to 10
g/ml), incubation times of longer than 30 min were employed
for granulocyte activation, or isolated cell cultures or plasma
were used. In addition, it was recently shown that a contami-
nating substance of commercially available LPS is, at least in
part, responsible for the upregulation of neutrophil responses
(20). We claim that the conditions used in our study more
closely resemble the in vivo situation than those used in pre-
vious studies. In our model, purified NmLPS was tested in
whole blood at concentrations that are relevant for the situa-
tion encountered during FMS. The relatively short incubation
times mimic the function of the complement cascade system,
the components of which are present in plasma and able to be
immediately activated by an invading pathogen, in this way
avoiding the contribution of activation processes secondary to
other inflammatory events.
We propose that the observed weak complement-activating
property of NmLPS is not specific for this type of LPS, as it has
a relatively short saccharide side chain, but that other types of
LPS are also weak complement activators at relevant concen-
trations. Preliminary data from our laboratory suggest that this
is the case for E. coli LPS in the same in vitro model. In
addition, in primate models, complement is not activated after
E. coli LPS infusion, but after whole E. coli cell infusion,
marked complement activation occurs within 15 min (15, 37).
Also, in a human endotoxemia model, no complement activa-
tion is observed, whereas significant cytokine production, en-
dothelial cell activation, and activation of the coagulatory and
fibrinolytic systems are found (36a).
The bacterial components that are involved in the activation
of complement, the upregulation of CR3 expression, and oxi-
dative burst remain elusive and will be subjected to further
investigation. It was previously reported that OMVs isolated
from LPS-deficient N. meningitidis induce substantial comple-
ment activation (1). This suggests that the non-LPS compo-
nents that induce complement activation reside in the outer
membrane. The lectin pathway seems to be an important
player in complement activation by meningococci when they
are grown on Kellog’s medium and studied in the whole blood
model (1, 29). Since mannose-binding lectin binding to the
bacteria occurs via the outer membrane proteins porin and
opacity protein (OpA) independently of LPS (9a), it is reason-
able to suggest that the porins and OpA are responsible, at
least in part, for the observed complement activation and sub-
sequent CR3 upregulation and oxidative burst.
The proinflammatory cytokines TNF- and IL-1 are pri-
mary cytokine mediators during meningococcal sepsis, whereas
IL-8 and MIP-1 are important chemotactic proteins that are
important for pathogenesis (14, 36, 39). We found that LPS
N. meningitidis induced marked IL-8, and to a lesser extent,
TNF- and MIP-1 production in the whole blood model,
indicating that bacterial components other than LPS are also
proficient at inducing cytokine or chemokine production. How-
ever, LPS N. meningitidis was more potent in the induction of
these proinflammatory mediators, in particular TNF- and
MIP-1, indicating that LPS is an important factor involved in
the regulation of these processes, which is in agreement with
previous reports (27, 30, 34). It is tempting to speculate that
the observed LPS-independent induction of IL-8, and possibly
also TNF- and MIP-1, is mediated or potentiated by the
activation of complement factor C5a, as has been suggested
previously (7, 22, 26).
We conclude that complement activation occurs indepen-
dently of the LPS moiety of N. meningitidis. Therefore, CR3
upregulation and oxidative burst, previously shown to be highly
complement dependent, are also independent of LPS. Cyto-
kine and chemokine production can be induced via LPS-de-
pendent as well as LPS-independent mechanisms.
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